<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00989521</url>
  </required_header>
  <id_info>
    <org_study_id>601-1V2</org_study_id>
    <nct_id>NCT00989521</nct_id>
  </id_info>
  <brief_title>Effect of PUR003 on Asthma</brief_title>
  <official_title>Double-blind, Placebo-controlled Crossover Evaluation of the Effect of PUR003 on Subjects With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulmatrix Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Joseph's Healthcare Hamilton / Firestone Institute for Respiratory Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pulmatrix Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PUR003 is an inhaled substance that is proposed to assist in the treatment of asthma.

      Study objectives are to :

        1. to evaluate the safety of PUR003 in subjects with asthma, and

        2. to evaluate the efficacy of PUR003 in assisting the treatment of asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of PUR003 as determined by incidence of adverse events (AEs); changes in physical examination, chest examination; pulmonary function; vital signs; electrocardiogram (ECG) and clinical laboratory assessments.</measure>
    <time_frame>after three doses</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Asthma</condition>
  <condition>Lung Diseases</condition>
  <condition>Bronchial Diseases</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline for inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PUR003</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PUR003 for inhalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PUR003</intervention_name>
    <description>PUR003 for inhalation</description>
    <arm_group_label>PUR003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline for inhalation</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent.

          2. Ability and willingness to return to the outpatient clinic for repeated clinic visits
             and complete all assessments.

          3. Adult male or female subject, 18-60 years of age.

          4. Stable, mild asthma not requiring any medical treatment other than short acting
             inhaled bronchodilators, as needed.

          5. No smoking within six months prior to entry

          6. Must be medically stable.

          7. Female subjects must have a negative pregnancy test

          8. Subjects of child bearing potential should be sexually inactive (abstinent) for 14
             days prior to the first dose of study medication or using an acceptable form of birth
             control methods.

        Exclusion Criteria:

          1. History or presence of significant co-existing chronic diseases.

          2. History of asthma exacerbations or upper or lower respiratory illness (viral
             respiratory syndrome, bronchitis, pneumonia) within four weeks of first visit.

          3. Pregnancy, breastfeeding.

          4. Abused alcohol or illicit drugs that required treatment.

          5. Participated in any other investigational drug evaluation within last 30 days.

          6. Scheduled to have elective or invasive medical intervention, procedure, or surgery
             within 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parameswaran Nair, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph's Healthcare Hamilton / Firestone Institute for Respiratory Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Firestone Institute for Respiratory Health</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2009</study_first_submitted>
  <study_first_submitted_qc>October 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2009</study_first_posted>
  <last_update_submitted>November 21, 2011</last_update_submitted>
  <last_update_submitted_qc>November 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Parameswaran Nair, MD, PhD, FRCP, FRCPC</name_title>
    <organization>Firestone Institute for Respiratory Health</organization>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>bronchial diseases</keyword>
  <keyword>lung diseases</keyword>
  <keyword>bronchitis</keyword>
  <keyword>respiratory tract diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Bronchial Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

